In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
Binding of growth factors and cytokines to their cognate receptors on cell membranes triggers their endocytosis and degradation in lysosomes, thus providing a physiologically important negative feedback mechanism for cell signalling.
The ESCRT-II complex recognizes ubiquitinated receptors in the endosomal membrane, thus initiating their sorting to degradative lysosomes. (click to enlarge image)It is not known in detail how endocytosed receptors are trafficked to the degradative lysosomes, but work in Harald StenmarkÂ’s lab has uncovered several factors involved in this process. Among these are the so-called endosomal sorting complexes required for transport (ESCRTs), and Thomas Slagsvold in StenmarkÂ’s group has previously shown that the so-called GLUE domain in the ESCRT-II complex binds ubiquitin .
In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
From major journals, first or last author from the Institute for Cancer Research
Pettersen S, Øy GF, Egeland EV, Juell S, Engebråten O, Mælandsmo GM, Prasmickaite L(2023) Breast cancer patient-derived explant cultures recapitulate in vivo drug responses Front Oncol, 13, 1040665 DOI 10.3389/fonc.2023.1040665, PubMed 36910663
Chauhan SK, Casado RB, Landsverk OJB, Johannessen H, Phung D, Nilsen HR, Sætre F, Jahnsen J, Horneland R, Yaqub S, Aandahl EM, Lundin KEA, Bækkevold ES, Jahnsen FL(2023) The human small intestine contains two functionally distinct regulatory T-cell subsets J Allergy Clin Immunol(in press) DOI 10.1016/j.jaci.2023.02.030, PubMed 36893861
Ghiasvand R, Berge LAM, Andreassen BK, Green AC, Al Rahmoun M, Fournier A, Kvaskoff M, Veierød MB, Robsahm TE(2023) Statin use and risk of cutaneous melanoma: A nationwide nested case-control study Br J Dermatol(in press) DOI 10.1093/bjd/ljad057, PubMed 36866569
Arjona-Sanchez A, Martinez-López A, Moreno-Montilla MT, Mulsow J, Lozano-Lominchar P, MartÃnez-Torres B, Rau B, Canbay E, Sommariva A, Milione M, Deraco M, Sgarbura O, Torgunrud A, Kapenekian V, Carr NJ, Hoorens A, Delhorme JB, Wernert R, Goere D, Martin-Roman L, Cosyns S, Flatmark K, Davidson B, Khellaf L, Pereira-Perez Fet al.(2023) External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification Eur J Surg Oncol(in press) DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222
Humbert M, Olofsson A, Wullimann D, Niessl J, Hodcroft EB, Cai C, Gao Y, Sohlberg E, Dyrdak R, Mikaeloff F, Neogi U, Albert J, Malmberg KJ, Lund-Johansen F, Aleman S, Björkhem-Bergman L, Jenmalm MC, Ljunggren HG, Buggert M, Karlsson AC(2023) Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age Proc Natl Acad Sci U S A, 120(12), e2220320120 DOI 10.1073/pnas.2220320120, PubMed 36917669
Halkola AS, Joki K, Mirtti T, Mäkelä MM, Aittokallio T, Laajala TD(2023) OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer PLoS Comput Biol, 19(3), e1010333 DOI 10.1371/journal.pcbi.1010333, PubMed 36897911
